Europe Breast Cancer Therapeutics Market Report 2022 to 2030

Europe Breast Cancer Therapeutics Market Analysis

$ 3999

The Europe breast cancer therapeutics market size was valued at $3.45 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.64% from 2022 to 2030 and will reach $8.34 Bn in 2030. The main factors propelling the Europe breast cancer market are the implementation of breast cancer screening programs and increased research and development initiatives for new drug developments in Europe. The market is segmented by therapy, by cancer type, and by distribution channel. Mylan, AstraZeneca, and Celltrion are some of the main market players in the Europe breast cancer therapeutics market.

ID: IN10EUPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Europe AUTHOR: Parul Choudhary

Buy Now

Europe Breast Cancer Therapeutics Market Executive Analysis

The Europe breast cancer therapeutics market size is at around $3.45 Bn in 2022 and is projected to reach $8.34 Bn in 2030, exhibiting a CAGR of 11.64% during the forecast period. More than any other EU Member State, current healthcare spending in Germany and France was comparable to 12.8% and 12.2% of GDP, respectively. Austria (11.5%), Sweden (11.4%), the Netherlands (11.1%), and Belgium (11.1%) had the next-highest rates. Only three other EU members, Spain, Portugal, and Denmark, had double-digit rates. 11.8% of Switzerland's GDP is being spent on healthcare, while Norway likewise has a double-digit ratio. In comparison, less than 7.5% of GDP was spent on current healthcare in six Member States, with Luxembourg having the lowest %age (5.8%).

The European Cancer Information System (ECIS) forecasts that breast cancer will continue to be the most prevalent cancer in women, accounting for 29.2% of all malignancies in females in the European Union (EU-28). A total of 404,920 new cases of female breast cancer were predicted to be diagnosed in the EU-28 nations in 2018, translating to an age-adjusted standardized rate (ASR) of 144.9/100,000. Less than 5% of occurrences of breast cancer occur in those under the age of 35, whereas 75% of cases affect adults over the age of 50. With a median age of 41.9 years compared to a global median age of 29.2 years, demographic trends in Europe indicate an aging population. The burden of breast cancer and its effects on public health will continue to rise as the EU's population ages. To provide the most individualized, secure, and effective therapy, treatment options are dependent on the grade, stage, and breast cancer molecular subtype. The grade reflects how tumor cells differ from normal cells in terms of appearance. In order to treat non-metastatic breast cancer, the tumor is removed completely or with breast preservation surgery, followed by systemic therapy such as chemotherapy and targeted therapy, as well as preoperative (neoadjuvant) or postoperative (adjuvant) radiotherapy. Endocrine therapy for hormone receptor-positive (HR+) breast cancer and anti-HER2 therapy for HER2+ breast cancer make up targeted therapy. For the triple-negative breast cancer subtype, there is sadly no available targeted therapy.

europe breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The development of the Europe breast cancer therapeutics market is anticipated to be aided by the implementation of breast cancer screening policies and programs to reduce the incidence and mortality rates related to the disease. The demand for the Europe breast cancer therapeutics market is also expected to rise in parallel with variables that support drug development, such as increased R&D spending and oncology developments.

Market Restraints

The primary inhibitor of the Europe breast cancer therapeutics market is the patent expiration of certain medications. The expansion of the Europe breast cancer therapeutics market is also hampered by strict guidelines and regulations, as well as the side effects of chemotherapy.

Competitive Landscape

Key Players

Mylan
AstraZeneca
Celltrion
Bristol-Myers Squibb
Fresenius Kabi
Eisai
Baxter Healthcare
GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

Countries in Europe have created a variety of reimbursement methods or policy tools to build their benefits packages. The product-specific eligibility model, which gives priority to specific medications and their indications, is the most widely used method. Mixed models are frequently created to address the protection of those who are more vulnerable, ensure protection against cancer-related poverty, and reduce inequities. Generally speaking, public health insurance programs in the majority of European nations cover the cost of breast cancer screening, diagnosis, and treatment, for example, all eligible persons in the UK are covered by the National Health Service for the cost of breast cancer screening, diagnosis, and treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.